Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07632352

Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma

Based on the bioholographic theory, this study preliminarily explores the clinical efficacy of hand acupuncture in treating acute exacerbation of bronchial asthma and evaluates its immediate anti-asthmatic effect, so as to provide a new therapeutic strategy for the clinical management of bronchial asthma.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

the First Affiliated Hospital of Henan University of Chinese Medicine

Zhengzhou, Henan, 450000, China

Location status: Recruiting

Location contact

Qinmei Yang

CONTACT

[email protected]

15981845716

About this study

This study adopted a randomized controlled trial design, with patients in the acute exacerbation phase of bronchial asthma as the research subjects. A total of 72 patients who met the inclusion criteria were randomly divided into the acupuncture group and the control group in a 1:1 ratio. The control group received standard Western medicine treatment, while the acupuncture group was given acupuncture treatment based on biological holography theory in addition to the standard Western medicine treatment. The acupoints selected were Kechuan point, New Kechuan point, and Yuji point. The treatment was administered once a day for 20 minutes each time, for 5 consecutive days, with a 3-month follow-up. The therapeutic efficacy of manual acupuncture in treating acute exacerbation of bronchial asthma was evaluated with indicators including symptom and sign scores, pulmonary function, ACT , mMRC , Mini-AQLQ scale, serum interleukin-4 (IL-4), serum eotaxin and specific immunoglobulin E (SIgE). In addition, the underlying therapeutic mechanism was preliminarily explored to formulate a technical protocol for rapid anti-asthma acupuncture, laying a foundation for long-term and objective efficacy evaluation of this therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients meeting the Western medicine diagnostic criteria for acute exacerbation of bronchial asthma
  • Aged ≥ 18 years old
  • Voluntarily receive treatment and sign the informed consent form

Exclusion criteria

  • Those who fail to meet the inclusion criteria
  • Patients suffering from other severe systemic diseases such as diseases of the circulatory system, hematological system and nervous system
  • Pregnant or lactating women
  • Subjects enrolled but not treated per the study protocol
  • Patients who have participated in other clinical trials of medicinal products within 3 months
  • Other circumstances deemed ineligible for enrollment by researchers

Treatment and study plan

Acupuncture

Other

The acupoints selected were Kechuan point, New Kechuan point, and Yuji point. The treatment was administered once a day for 20 minutes each time, for 5 consecutive days.

Standard Western Medicine Treatment

Drug

Evaluate and manage in accordance with the Chinese Expert Consensus on Assessment and Management of Acute Exacerbation of Bronchial Asthma issued by the Asthma Group of the Chinese Thoracic Society, Chinese Medical Association in 2018 and the Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 ).

Primary outcomes

  1. Peak Expiratory Flow(PEF)

    Time frame: After treatment on Day 5 and follow-up at 1, 2 and 3 months

    PEF will be used to assess pulmonary function

  2. Asthma Control Test

    Time frame: After treatment on Day 5 and follow-up at 1, 2 and 3 months

    The ACT score consists of 5 questions, each scored from 1 to 5 points, with a total score ranging from 5 to 25 points; lower scores indicate more severe symptoms.

Secondary outcomes

  1. Forced expiratory volume in first second/pred(FEV1%pred)

    Time frame: After treatment on Day 5 and follow-up at 1, 2 and 3 months

    FEV1%pred will be used to assess pulmonary function

  2. Clinical Symptom and Sign Score

    Time frame: After treatment on Day 5 and follow-up at 1, 2 and 3 months

    It includes six symptoms: cough, expectoration, chest tightness, wheezing, shortness of breath and wheeze. Scores of 0, 3, 6 and 9 are assigned according to the severity of symptoms, with higher scores corresponding to more severe symptoms.

  3. Mini Asthma Quality of Life Questionnaire(Mini-AQLQ)

    Time frame: After treatment on Day 5 and follow-up at 1, 2 and 3 months

    It consists of 15 questions, each scored on a scale from 1 to 7 based on the severity of symptoms and their degree of impact. A score of 1 indicates no symptoms or no adverse impacts, while a score of 7 stands for severe symptoms or substantial impairment. Lower total scores correspond to a higher quality of life.

  4. modified Medical Research Council (mMRC)

    Time frame: After treatment on Day 5 and follow-up at 1, 2 and 3 months

    Scores range from 0 to 4 based on the severity of dyspnea, with higher scores indicating more severe symptoms.

  5. Interleukin 4 (IL-4)

    Time frame: After treatment on Day 5

    Detect the level of IL-4 in peripheral blood

  6. Eotaxin

    Time frame: After treatment on Day 5

    Detect the level of Eotaxin in peripheral blood

  7. IgE

    Time frame: After treatment on Day 5

    Detect the level of IgE in peripheral blood

Study contacts

Contact information is provided by the study sponsor or research team.

Qinmei Yang

CONTACT

[email protected]

15981845716

Sponsors and collaborators

Lead sponsor

Henan University of Traditional Chinese Medicine

Other

Registry information

Official study title

Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma Based on Biological Holography Theory

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jun 8, 2026
Registry last updated
Jun 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.